Adjuvant immunotherapy has recently become a treatment option for patients with melanoma and sentinel lymph node biopsy (SLNB) plays a critical role in identifying the subset of patients at high risk of recurrence or relapse following complete resection who may benefit.
This 4-part series explores the latest clinical evidence and recommendations for adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma, discusses which patients are appropriate for SLNB, what this procedure involves and how the results of SLNB should guide adjuvant therapy.
It also explores practical aspects of care with a focus on the importance of early identification and contains a case study.
This program is supported by an independent educational grant provided from Bristol Myers Squibb.